The process of apoptosis is carried out by a highly regulated and integrated series of signaling intermediates involving multiple organelles. Apoptosis can be initiated by DNA damage in the nucleus, stress sensed by the endoplasmic reticulum, or death receptor activation at the cell surface (Ferri and Kroemer, 2001 ). Initiation of apoptotic signaling by the internal or intrinsic pathway is regulated in part by Bcl-2 family proteins (i.e. Bax, Bak) that can directly trigger the release of proapoptotic mediators from the mitochondria, and in turn activate the initiator caspase-9 (Danial and Korsmeyer, 2004) . Activation of death receptor pathway directly activates initiator caspases such as caspase-8 (Thorburn, 2004) . These two pathways can cross-activate in certain cells via the caspase-8-mediated cleavage and mitochondrial translocation of Bid (Esposti, 2002) . Common to apoptosis induced by a wide variety of genotoxic agents and death ligands is the activation of the effector caspases such as caspase-3. The activation of effector caspases triggers the cleavage of death substrates that systematically commit the cell to an apoptotic cell fate. The death substrates cleaved by caspases include nucleases involved in degrading DNA, cell-cycle proteins that limit cell proliferation, and other caspases that amplify the caspase proteolytic cascade (Degterev et al, 2003) .
Protein kinase C (PKC)d is a widely expressed caspase-3 substrate that becomes activated by proteolysis in response to apoptotic stimuli such as DNA damaging drugs, UV or ionizing radiation, and death ligands (Emoto et al, 1995; Ghayur et al, 1996; Mizuno et al, 1997; Denning et al, 1998; Khwaja and Tatton, 1999; Reyland et al, 1999; Basu et al, 2001; Brodie and Blumberg, 2003) . PKCd belongs to the PKC family of serine/threonine protein kinases that consist of at least nine isoforms having either pro-or antiapoptotic activities (Gutcher et al, 2003) . Classical (a, b, g) and novel (d, e, Z, y) PKC isoforms can be activated by the diacylglycerol generated in response to phosphatidylinositol turnover, however, caspase-mediated cleavage in the hinge domain can also activate PKC by removing the inhibitory effect of the pseudosubstrate domain in the regulatory domain, and is thus independent of phospholipid hydrolysis (Stabel and Parker, 1991; Ghayur et al, 1996; Denning et al, 2002) . PKCd is an especially noteworthy caspase-3 substrate because expression of the catalytic fragment cleavage product in several cell types is sufficient to induce apoptosis (Ghayur et al, 1996; Bharti et al, 1998; Denning et al, 2002; DeVries et al, 2002; Leverrier et al, 2002; Brodie and Blumberg, 2003) . Despite PKCd being a caspase-3 target cleaved and activated relatively late in the death effector-signaling pathway, inhibition or targeted inactivation of PKCd can reduce apoptosis induced by UV radiation, chemotherapeutic drugs, and oxidative stress (Denning et al, 1998; Reyland et al, 1999; Leitges et al, 2001; Majumder et al, 2001; Matassa et al, 2001; Denning et al, 2002; DeVries et al, 2002; Matsumura et al, 2003) . Furthermore, inhibition of PKCd catalytic activation also abrogates caspase activity induced by UV and DNA damaging drugs (Reyland et al, 1999; Basu et al, 2001; Denning et al, 2002) .
Together these results indicate that the cleavage and activation of PKCd sets up a positive feedback loop that impinges upon more upstream components of the death effector pathway, amplifying the caspase cascade and helping to irreversibly commit cells to die.
In this study, we investigated the signaling pathways activated by the PKCd catalytic fragment in human keratinocytes to understand its role in inducing apoptosis. We found that the PKCd catalytic fragment activated the proapoptotic Bcl-2 family protein Bax and caused release of cytochrome c, activation of the caspase cascade, and loss of inner mitochondrial membrane integrity. Since caspase activation is responsible for cleaving and activating PKCd in the first place, these results explain the positive feedback regulation mediated by PKCd in cells committed to undergo apoptosis.
Results
Inducible activation of the PKCd catalytic fragment Expression of the PKCd catalytic fragment induces apoptosis in a wide variety of cells, including retroviral packaging cells . In order to generate high titer retrovirus encoding the PKCd catalytic domain, we constructed a PKCd catalytic fragment that can be regulated. To generate PKCdcatD-ER, we fused the PKCd catalytic domain to a mutant estrogen receptor ligand-binding domain that binds 4-hydroxytamoxifen (Tam) (Fig 1) . This fusion protein begins immediately after the caspase-3 cleavage site in the hinge domain of PKCd, and has the estrogen receptor ligand-binding domain at its carboxyl terminus. As shown in Fig 2A, infection of HaCaT cells with a retrovirus encoding the 78 kDa PKCdcatD-ER fusion protein caused high-level expression as detected by either a C-terminal PKCd antibody or an estrogen receptor antibody. A 43 kDa PKCd catalytic fragment was also detected with the PKCd antibody that probably represents the endogenous PKCd catalytic fragment generated by caspase cleavage, and this catalytic fragment was increased 1.7-fold by Tam treatment.
To determine if treating cells with Tam induced the enzymatic activity of the PKCdcatD-ER, we performed immunoprecipitation kinase assays on the total PKCd in HaCaT cells expressing either endogenous PKCd (Linker) or PKCdcatD-ER. As shown in Fig 2B, Diagram of the protein kinase C (PKC)dcatD-ER fusion protein. Full-length PKCd is cleaved in the hinge domain at DMQD 330 # by caspase-3 to generate an active catalytic domain fragment. PKCdcatD-ER consists of the PKCd catalytic domain beginning at the caspase-3 cleavage site fused to a mutant estrogen receptor ligand-binding domain (ER) at the carboxyl terminus. To construct PKCdcatD-ER, a methoinine (M) was added to initiate translation after the cleavage site, and a tryptophan (W) was added at the fusion site to keep the ER in frame. Figure 3A shows that there was morphological cell death in the PKCdcatD-ERexpressing cells in the presence and absence of Tam. The inactive kinase mutant (K378A) or control vector (Linker) did not cause any morphological effects, and Tam alone had no effect. Quantitation of apoptosis by Annexin V staining in Fig  3B shows that the PKCdcatD-ER increased the basal level of apoptosis about 1.5-fold from 10.1% to 14.7%, but the addition of Tam significantly increased apoptosis to 37.8%. The elevated apoptosis in the absence of Tam is consistent with elevated basal PKCd activity in PKCdcatD-ER-expressing cells (Fig 2B) . The PKCdcatD(K378A)-ER mutant did not trigger apoptosis, but UV radiation induced massive (79%) apoptosis. The general caspase inhibitor z-VAD provided 59% inhibition from UV apoptosis and also inhibited PKCdcatD-ER apoptosis to approximately the same extent (60% inhibition), indicating that PKCdcatD-ER apoptosis is largely caspase dependent. Expression of the PKCd catalytic fragment also induced ultrastructural features of apoptosis such as cytoplasmic vacuolization, membrane blebbing, and nuclear condensation and fragmentation (Fig 3C) . These ultrastructural changes were evident at 1 d after infection, and by 3 d were as prominent as those induced 18 h after UV irradiation.
Activation of caspases by the PKCd catalytic fragment To explore the relative contribution of intrinsic and death receptor pathways in PKCdcatD-ER apoptosis, we used dominant/negative mutants of caspase-9 and FADD. In HaCaT cells, the dominant/negative caspase-9 can selectively block the intrinsic apoptotic pathway (i.e. UV), wheras the FADD dominant/negative inhibits apoptosis induced by death receptor activation (Sitailo et al, 2002) . Figure 4A shows that the dominant/negative caspase-9 and FADD both inhibited apoptosis induced by PKCdcatD-ER to an equal degree ( $ 35%), indicating that both pathways may be involved. In contrast, UV-induced apoptosis was selectively blocked by the caspase-9 dominant/negative and z-VAD, whereas apoptosis induced by death receptor activation was inhibited by FADD dominant/negative and not caspase-9 dominant/negative. z-VAD partially inhibited apoptosis induced by PKCdcatD-ER plus Tam, confirming that caspase activity is required for apoptosis induced by the PKCd catalytic domain.
To directly determine which caspases are activated during apoptosis induced by PKCdcatD-ER, we measured caspase enzyme activity using peptide substrates selective for caspase-2, caspase-3, caspase-8, or caspase-9. As shown in Fig 4B , PKCdcatD-ER plus Tam induced the activity of caspase-3, caspase-8, and caspase-9 activity, but not caspase-2. The activity of the initiator caspases, caspase-8 and caspase-9, were increased approximately to the same extent ( $ 1.4-fold), precluding any assignment of a single initiator caspase. In contrast, UV induced the activity of all caspases, including caspase-2. The kinase-inactive PKCdcatD(K378A)-ER plus Tam did not induce caspase activation (data not shown). Although not evaluated, we predict that caspase activation by PKCdcatD-ER without Tam would be greater than Linker plus Tam but less than PKCdcatD-ER plus Tam, since the induction of apoptosis was intermediate (Figs 3B, 4A, and 5A).
Inhibition of PKCd-induced apoptosis by Bcl-2 To further evaluate the involvement of the intrinsic apoptotic pathway in PKCd apoptosis, we expressed the anti-apoptotic Bcl-2 in HaCaT cells. Figure 5A shows that apoptosis induced by PKCdcatD-ER plus Tam was inhibited $ 54% by Bcl-2 expression. Expression of full-length PKCd or treating Linkerinfected cells with TPA did not induce apoptosis, but the combination of full-length PKCd plus TPA-induced 26.1% apoptosis. Apoptosis induced by full-length PKCd plus TPA was also inhibited by Bcl-2 (59% inhibition), as was UVinduced apoptosis (57% inhibition). These results suggest that the intrinsic death effector pathways play a major role in apoptosis induced by either PKCd-cat or the activated fulllength PKCd.
The ability of Bcl-2 to inhibit apoptosis by PKCd-cat was confirmed by measuring loss of mitochondrial membrane potential. As shown in Fig 5B, Bcl-2, Bcl-x L , and z-VAD all inhibited the loss of mitochondrial membrane potential induced by PKCd-cat. Bcl-2 was most effective with 82% inhibition. Bcl-2 and Bcl-x L also slightly reduced the low level of membrane depolarization in PKCd(K378A)-cat-expressing cells, although the level of membrane depolarization in PKCd(K378A)-cat cells was not significantly different than Linker-infected control cells. Bcl-2 and Bcl-x L overexpression were confirmed by western blotting (data not shown).
The PKCd catalytic fragment induces Bax activation and cytochrome c release The release of cytochrome c from mitochondria is a triggering event for caspase activation and is negatively regulated by anti-apoptotic Bcl-2 family proteins (Cheng et al, 2001 ). Since Bcl-2 and Bcl-x L blocked apoptosis induced by PKCdcatD-ER, we investigated the ability of PKCdcatD-ER to cause cytochrome c release. In Fig 6A, consistent with mitochondrial localization. Cells expressing PKCdcatD-ER and treated with Tam had a marked redistribution of cytochrome c staining suggesting a perturbation in mitochondrial architecture. Disruption of mitochondria organization was confirmed with MitoTraker staining shown in Fig 7C. In addition, diffuse cytochrome c staining was evident in cells co-expressing high levels of PKCdcatD-ER (Fig 6A) , suggesting release of cytochrome c into the cytoplasm. Cytochrome c remained punctate in HaCaT cells expressing the inactive PKCdcatD(K378A)-ER, but UV irradiation caused cytochrome c to appear diffuse and clumpy. Cytochrome c release was confirmed in biochemically fractionated cells by western blots of cytosolic fractions (Fig 6B) . Expression of PKCdcatD-ER plus Tam treatment increase cytosolic cytochrome c, and this release was blocked by Bcl-2 and Bcl-x L . Cytochrome c was still released in the presence of the general caspase inhibitor z-VAD, consistent with cytochrome c release being upstream of caspase activation (Adrain et al, 2001) . Cytochrome c release induced by UV was also blocked by Bcl-2 and Bcl-x L .
The ability of Bcl-2 and Bcl-x L to block cytochrome c release and apoptosis suggests that pro-apoptotic Bcl-2 family proteins may be involved in initiating apoptosis by the PKCd catalytic fragment. We examined several Bcl-2 family proteins and found no change in the total levels of Bcl-2, Bcl-x L , and Noxa in cells expressing active PKCdcatD-ER (data not shown). Figure 7A shows that total Bax levels, however, were elevated 2.5 AE 0.4-fold (N ¼ 3 experiments) in cells infected with the PKCdcatD-ER virus, and Bax increased further in PKCdcatD-ER-expressing cells treated with Tam (4.5 AE 1.4-fold, N ¼ 3).
Bax can directly induce the release of cytochrome c from mitochondria (Jurgensmeier et al, 1998) , and oligomerization in the mitochondrial membrane is an essential component of its activation. PKCdcatD-ER-expressing HaCaT cells and normal keratinocytes treated with Tam had a modest but reproducible (three experiments) increase in the Bax dimer form in membrane extracts (Fig 7B) . The UV-positive control caused a large amount of Bax dimer to form in HaCaT cells and normal keratinocytes, with the trimer form also visible. PKCdcatD(K378A)-ER plus Tam did not induce Bax dimer formation in HaCaT cells.
The MitoTraker staining in Fig 7C shows that the active PKCdcatD-ER also caused a dramatic redistribution of mitochondria from an even, perinuclear ring to an asymmetric clump at one side of the nucleus. Bax was also redistributed from a cytoplasmic localization with a ring around the nucleus to a more focal bleb that partially co-localized with the MitoTraker staining. The inactive PKCdcatD(K378A)-ER did not cause redistribution of mitochondria or Bax. The Bax immunofluorescence staining was specific as it was completely blocked by pre-incubating the Bax antibody with a competing peptide. Taken together, these data indicate that the active catalytic domain of PKCd triggers the redistribution and activation of Bax, cytochrome c release, caspase activation, and ultimately apoptosis.
Discussion
Since the PKCd catalytic fragment is toxic to many cell types, we constructed a fusion protein with a mutant est- triggered higher basal apoptosis, but the activity and apoptosis were induced further by treating cells with Tam (Figs 2-4) . The induction of apoptosis was not immediate upon addition of Tam, and took 2-3 d of exposure before significant levels of apoptosis could be detected. Since the kinase inactive mutant PKCdCatD(K378A)-ER did not induce apoptosis, we conclude that apoptosis requires enzymatic activity of the PKCdCatD-ER fusion protein, as was the case for the PKCd-cat . In fact the effects of PKCdCatD-ER plus tamoxifen on keratinocytes appear identical and stronger than the effects we observe using a PKCd-cat construct, indicating that the fusion protein has no additional activities to the PKCd catalytic fragment . Apoptosis can also be induced by the activation of fulllength PKCd, and this has been associated with caspase activation and cytochrome c release in some cell types Majumder et al, 2000; Majumder et al, 2001; Matassa et al, 2001 ), but not all (Fujii et al, 2000) . The caspase dependency of apoptosis induced by PKCdcatD-ER was demonstrated by assaying caspase activity (Fig 4B) , and by inhibiting caspase activity and apoptosis with z-VAD and a caspase-9 dominant/negative ( Figs 3B and 4A) . The release of cytochrome c and induction of caspase activity by activation of full-length PKCd has been observed in some cell types Majumder et al, 2000; Majumder et al, 2001; Matassa et al, 2001 ). Caspase-3, caspase-8, and caspase-9 were all activated by PKCdcatD-ER, but since these caspases can cross-activate each other, it was not possible to determine which caspase is initially activated. Of note, UV induced robust activity of caspase-2, an initiator caspase implicated in pre-mitochondrial events, but the activation of the PKCd catalytic domain did not activate caspase-2 suggesting a non-caspase mechanism for initiating mitochondrial changes. Activation of caspase-2 by UV has been demonstrated previously, however, its processing is dependent on caspase-9 (Paroni et al, 2001) . Although caspase-2 was activated by UV, the general caspase inhibitor z-VAD did not bock cytochrome c release induced by UV.
Both the full-length and catalytic fragment of PKCd can redistribute to mitochondria Majumder et al, 2000; Majumder et al, 2001; Matassa et al, 2001; Denning et al, 2002) and nuclei DeVries et al, 2002) , and both subcellular localizations may well be involved in apoptotic signaling. Several substrates involved in apoptosis have been identified for PKCd, including p73b (Ren et al, 2002) , DNA-PK (Bharti et al, 1998) , Rad9 (Yoshida et al, 2003) , phospholipid scramblase 1 (Frasch et al, 2000) and 3 (Majumder et al, 2001) , and nuclear lamin B (Cross et al, 2000) . The phosphorylation and association of PKCd with these targets can explain several apoptotic processes. For example, plasma membrane phospholipid scramblase 1 and mitochondrial phospholipid scramblase 3 are both phosphorylated by PKCd and involved in the phosphatidylserine redistribution that occurs in apoptosis (Frasch et al, 2000; Majumder et al, 2001) . PKCd cleavage and activation triggers cytochrome c release and initiates the caspase cascade, and the PKCd substrates identified to date cannot explain these effects. Our results indicate that the PKCd catalytic fragment activates and causes the redistribution of Bax, which in turn can directly trigger cytochrome c release (Jurgensmeier et al, 1998) . The release of cytochrome c from mitochondria causes caspase activation via apoptosome formation (Zou et al, 1999) . Since HaCaT cells have two mutant p53 alleles, our data indicates that the catalytic fragment of PKCd can initiate apoptosis via an intrinsic pathway distinct from p53. This paradigm explains how the PKCd catalytic fragment can activate the intrinsic death effector pathway resulting in a positive feedback loop between caspase activation and PKCd activation.
The mechanism of Bax activation by the PKCd catalytic domain requires its kinase activity, but could be direct or indirect. The Bcl-2 family proteins are regulated by phosphorylation and protein-protein interaction. For example, phosphorylation of Bcl-2 is required for its anti-apoptotic function, whereas phosphorylation of Bad inhibits its proapoptotic activity (Datta et al, 1997; Ito et al, 1997) . Computer sequence analysis of human Bax-a at low stringency revealed potential PKC phosphorylation sites at T174 and T186 near its carboxyl terminus. PKCe can bind to Bax and inhibits its activation, thus promoting survival of prostate cancer cells (McJilton et al, 2003) . We did not detect any association between the catalytic domain of PKCd and Bax by co-immunoprecipitation (data not shown), and thus a direct protein-protein interaction is unlikely. Bcl-2 family proteins with multiple BH domains, such as Bax, are activated by BH3 domain-only proteins (i.e. Bad, Bid, Bim, Noxa) that function as sensors for apoptotic stimuli (Cory and Adams, 2002) . These BH3 domain-only molecules are kept inactive by binding to anti-apoptotic family members (i.e. Bcl-2, Bcl-x L , Mcl-1) (Cheng et al, 2001) , and thus it is possible that the primary target of the PKCd catalytic domain is a BH3 domain-only protein or an anti-apoptotic Bcl-2 family member.
In summary, cleavage and activation of the widely expressed PKCd occurs in many cells undergoing apoptosis. This apoptotic effector is known to feed back and stimulate more upstream components of the death effector pathway Majumder et al, 2000; Basu et al, 2001; Majumder et al, 2001; Matassa et al, 2001; Denning et al, 2002; Leverrier et al, 2002) . Our results identify Bax as a target activated by PKCd that can enhance apoptotic signaling by causing cytochrome c release and further stimulating caspase activation. These results have special implications for cells with reduced PKCd levels or activity, such as keratinocytes with activated ras, since these cells are lacking a critical death effector and may be relatively resistant to cell death by apoptosis (Denning et al, 1993; Geiges et al, 1995; Denning et al, 1996) .
Materials and Methods
Antibodies and chemicals PKCd was detected using an antibody against the catalytic domain (sc-937, Santa Cruz Biotechnology Inc., Santa Cruz, California) at 1:4000 for western blotting and 1:100 for immunofluorescence. Cytochrome c was detected using a monoclonal antibody (556432, BD Biosciences, San Diego, California) at 1:60 for immunofluorescence, and a polyclonal antibody (K2016, BD Biosciences) at 1:500 for western blotting. Bax was detected with a polyclonal antibody (sc-493, Santa Cruz Biotechnology Inc.) at 1:500 for western blotting and 1:80 for immunofluorescence. The mitochondrial probes Rhodamine 123 and MitoTraker Red CMXRos were from Molecular Probes (Eugene, Oregon). The fluorogenic substrates for caspase-9 (Ac-LEHD-AFC), caspase-8 (Ac-IETD-AFC), caspase-3 (Ac-DEVD-AFC), caspase-2 (Ac-VDVAD-AFC), and the general caspase inhibitor z-VAD-FMK were from Enzyme Systems Products (Livermore, California). Tam was from Sigma Chemical Company (St Louis, Missouri).
Caspase and PKC assays Caspase activity was assayed as previously described (Sitailo et al, 2002) . Briefly, attached and floating cells were lysed in 2 Â caspase lysis buffer: 25 mM HEPES-NaOH, pH 7.4, 10% sucrose, 0.1% CHAPS, 2 mM EDTA, 5 mM dithiothreitol. Cell lysates were spun in a microfuge, and 50 mg protein mixed with an equal volume of 2 Â caspase assay buffer: 25 mM HEPES-NaOH, pH 7.4, 5 mM dithiothreitol; containing 100 mM final concentration of the appropriate fluorogenic caspase substrate. Assays were incubated at 371C overnight and fluorescence was measured on a CytoFluor Multi-Well Plate Reader (Perceptive Biosystems).
For PKC assays, cells were treated and lysed in 20 mM TrisHCl, pH 7.4, 2 mM EDTA, 5 mM EGTA, 250 mM sucrose, 5 mM 2-mercaptoethanol, 1 Â Complete Protease Inhibitor Cocktail (Boehringer Mannheim, Indianapolis, Indiana), and 0.3% Triton X-100, and spun in a microfuge. Twenty to 30 mg of protein was assayed in assay buffer: 50 mM Tris-HCl, pH 7.4, 250 mg per mL BSA, 1 mM EGTA, 1.5 mM MgCl 2 , 10 mM of the general PKC substrate [ser 25 ]peptide (Life Technologies Inc, Gaithersburg, Maryland) in the presence of 25 mM ATP containing 1 mCi [g-32 P]ATP. Reactions were incubated for 10 min at 301C, spotted onto P81 phosphocellulose disks, washed extensively, and the associated radioactivity counted. Note that these assay conditions contain no lipids or phorbol esters to activate PKC.
Cell culture and virus infections
The immortalized human keratinocyte cell line HaCaT (Boukamp et al, 1988) , kindly provided by Dr Norbert Fusenig (German Cancer Research Center, Heidelberg, Germany), was cultured in Media 154 (Cascade Biologics Inc., Portland, Oregon) with 0.07 mM calcium added. For retroviral infections, cells were plated in six-well plates at 10 5 cells per well, and spin infected in the presence of 4 mg per mL polybrene (Hexadimethrine Bromide, Sigma Chemical Company). Cells were washed twice the next morning and fed with Media 154 with or without 100 nM Tam. In some experiments, cells were infected once in the morning and then again in the afternoon to introduce two different viruses. Cells were routinely assayed 3 d after infection. Experiments using normal human keratinocytes from foreskins were approved by Loyola University Medical Center's Institutional Review Board.
Cell fractionation and immunoblotting For fractionation into cytosol and mitochondria-enriched heavy membrane fractions, the plasma membrane was selectively permeabilized with 0.05% digitonin (Yi et al, 2003) . Cells were trypsinized, washed once in PBS, and suspended in isotonic sucrose buffer: 250 mM sucrose, 10 mM HEPES, pH 7.4, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EGTA, 1 mM dithiothreitol, 1 Â Complete Protease Inhibitor Cocktail. Digitonin was added to 0.05% final concentration and the cells mixed gently for 2 min at room temperature. The permeabilized cells were spun at 750 Â g at 41C to pellet nuclei and unbroken cells. The supernatant from this spin was spun at 10,000 Â g for 25 min at 41C to pellet the heavy membranes, including mitochondria. The supernatant was spun at 100,000 Â g for 1 h at 41C and this supernatant was taken as the cytoplasmic fraction.
For Bax cross-linking experiments, cells were collected by brief trypsinization, washed with PBS, and suspended in 160 mL PBS. Proteins were cross-linked with 0.5% formaldehyde with shaking at room temperature for 30 min as described (Mikhailov et al, 2001 ). Cross-linking was quenched by adding 2 volumes of 2% glycine. The cells were spun, washed with PBS, and suspended in isotonic sucrose buffer. After permeabilization with 0.05% digitonin for 2 min at room temperature, the cells were spun at 15,000 Â g for 10 min at 41C, and the membrane fraction-containing pellet was extracted for SDS-PAGE analysis. Whole-cell lysates for western blotting were prepared by lysing cells in 20 mM Tris-HCl, pH 7.5, 1% Triton X-100, 5 mM EDTA, and 1 Â Complete Protease Inhibitor Cocktail.
DNA constructs and retrovirus production To avoid the toxic effects of expressing the constitutively active PKCd catalytic fragment, we constructed a retrovirus encoding the human PKCd catalytic domain under the control of the estrogen receptor ligandbinding domain (Littlewood et al, 1995) . The PKCd catalytic fragment was PCR amplified from pKS-PKCd , and cloned in frame into LZRS-MycER containing the modified estrogen receptor ligand-binding domain of c-MycER (Littlewood et al, 1995) . MycER, kindly provided by Dr Gerard I. Evan (University of California at San Francisco Cancer Center), was cloned into the EcoRI site of LZRS-Linker (Kinsella and Nolan, 1996; Denning et al, 2002) . The resulting LZRS-MycER was digested with BamHI to remove c-Myc, and the BamHI-digested PKCd PCR product was cloned into the BamHI digested LZRS-MycER. The resulting construct, LZRS-PKCdcatD-ER, has the PKCd catalytic domain fused to the estrogen receptor ligand-binding domain. A kinase inactive version, LZRS-PKCdcatD(K378A)-ER, was constructed in the same fashion using the C3 domain ATP-binding site point mutant pKS-PKCd(K378A) as the template for PCR . This kinase inactive mutant did not induce apoptosis or associated biochemical changes in cells treated with Tam, and was included in several experiments to demonstrate this point ( Figs 3A,  B , 5B, 6A, 7B, and C). In some experiments, a virus encoding only the PKCd catalytic domain (PKCd-cat) was used .
The Bcl-2 and Bcl-x L retroviruses were constructed by inserting the cDNAs (provided by Gabriel Nuñ ez, The University of Michigan Medical School, Ann Arbor, Michigan) for Bcl-2 and Bcl-x L into LZRS. The Bcl-2 cDNA was cloned into LZRS that had been digested with BamHI, blunted with Klenow, and digested with NotI to generate LZRS-Bcl-2. The Bcl-x L cDNA was cloned into the EcoRI site of LZRS-Linker to generate LZRS-Bcl-x L .
Retroviruses were produced in the Phoenix-Ampho packaging line (ATCC with permission from Garry P. Nolan, Stanford University Medical Center) by calcium phosphate transfecting the LZRS constructs described above. After transfection, cells were selected and expanded in the presence of 1 mg per mL puromycin, and virus was harvested from confluent dishes cultured for 24-48 h at 321C. As a negative control, cells were infected with virus produced from the empty retroviral vector, LZRS-Linker.
Immunofluorescence For cytochrome c and PKCd immunofluorescence, cells were cultured on glass coverslips, washed with PBS, and fixed with 3.7% formaldehyde containing 0.05% saponin for 10 min at room temperature. For MitoTraker Red and Bax staining, cells were cultured with 100 nM MitoTraker Red for 30 min, washed, and then fixed in -201C acetone/methanol for 10 min. Coverslips were then washed extensively in FA buffer (Difco Labs, Detroit, Michigan) and stained with primary antibodies in PBS-containing normal goat serum (1:20 dilution) for 1 h at room temperature. Coverslips were washed again in FA buffer, and stained with secondary antibody conjugated to Alexa Fluor 488 (Molecular Probes) at 1:400 in PBS-containing normal goat serum (1:20 dilution). Coverslips were mounted on glass slides in 40% polyvinyl alcohol (300-70,000 MW) in glycerol, and the cells viewed with an Olympus AX80 fluorescent microscope (Olympus America, Inc., Melville, New York).
Flow cytometry Apoptosis was routinely assayed by flow cytometry using the Annexin V-FITC kit (Beckman Coulter Inc., Fullerton, California) as recommended by the manufacturer. The cells were then run on a Coulter Epics XL-MCL flow cytometer to determine the percentage Annexin V positive. The percent inhibition of apoptosis was calculated based on the apoptosis induced by the treatment (maximum apoptosisÀbaseline apoptosis).
Mitochondrial membrane potential was measured by Rhodamine 123 fluorescence. After infection and/or treatments, cells were trypsinized and incubated for 20 min in 1 mL of room temperature media containing 5 mM Rhodamine 123. The cells were washed with PBS and Rhodamine 123 fluorescence measured by flow cytometry. Cells with reduced fluorescence were counted as having lost their mitochondrial membrane potential.
